In 2012, iTeos spun off from Ludwig Cancer Research and de Duve Institute at UCL to create new drugs educating the immune systems of patients to fight against their cancers. Through a partnership with Pfizer, our first drug is now in clinical trials and iTeos has attracted a team of 40 people with 14 different nationalities to develop the next generation of cancer drugs. Based in Gosselies, iTeos has the ambition to become an world-class player with several new programs in clinical trials within the 3 coming years.
CTA
Sign up
Complete the application form and adhere to the Charter of Brand Ambassadors
